Carl Bjartmar, MD, PhD

Key expertise includes clinical development within orphan, neuromuscular, neurology and oncology indications including developing clinical plans with FDA, EMA and PMDA, successful completion of phase I-IV studies, and new drug approvals. Before joining Augustine, from 2023 Carl was an Independent Consultant at the management consultancy business BjartmarMed AB. Prior to this Carl held several executive leadership positions including CMO at Ascelia Pharma AB, in Malmö, Sweden from 2018-2022 and CMO at Wilson Therapeutics AB from 2015 until 2018 when the business was acquired by Alexion Pharmaceuticals at a 70% premium. Earlier roles include as a Senior Medical Director at Genzyme, a Sanofi company 2008-2015, leading neurology and orphan neuromuscular development programs and as a Specialist at Lundbeck A/S 2002-2008. He is a Board member of iCoat Medical AB and has authored more than 30 international publications (peer-reviewed articles, review articles, book chapters). Carl received his MD and Ph.D. from the Faculty of Health Sciences, University of Linköping, Sweden, and was subsequently a Postdoctoral Fellow at the Department of Neurosciences, Cleveland Clinic Foundation, Cleveland, OH, USA 1998-2002.